The opportunity associated with the Allogeneic Cell Therapy Market is projected to grow at a CAGR of 14.5% till 2035, claims Roots Analysis

Published: August 2023

Allogeneic cell therapies have emerged as a promising and rapidly advancing modality owing to their various benefits, including off-the-shelf availability, donor flexibility, reduced treatment time, broader applicability, relatively lower cost and easy scalability; some of the recently approved allogeneic cell therapies include, OMISIRGE (Gamida Cell), Tab-cel® (Atara Biotherapeutics and Stempeucel  (Stempeutics Research)

Roots Analysis has announced the addition of Allogeneic Cell Therapy Market, 2023 – 2035 report to its list of offerings.

Several industry players and academic / research institutes across the world are investigating different types of allogeneic cell therapies (such as stem cell therapies, T-cell therapies, natural killer cell therapies and dendritic cell therapies) to treat a multitude of indications. Further, advancements in gene editing technologies, cell manufacturing techniques and genetic engineering tools have significantly contributed to the progress in this domain, by enhancing their therapeutic potential and reducing the risk of immune rejection.  

To order this 220+ page report, which features 145+ figures and 135+ tables, please visit this link

Key Market Insights 

Over 480 allogeneic cell therapies are either approved or being investigated in research studies by more than 190 players

Around 70% of the aforementioned therapies are being evaluated in early stages of development (phase I and phase II). It is worth mentioning that 40% of these therapies are derived from peripheral blood, followed by those derived from umbilical cord (19%). Further, most (86%) of the pipeline candidates are being evaluated as monotherapies, followed by those developed in combination with other therapeutic agents (14%).

Significant increase in the Partnerships and Collaborations have Fueled Allogenic Cell Therapy Market Growth

Majority of the agreements related to allogeneic cell therapies were observed to be research and development agreements, representing around 25% of the total partnerships inked in this industry. Further, most of the intercontinental, as well as intracontinental deals have been inked by players based in North America.

Around USD 8.8 billion has been invested by both private and public investors, during 2019-2023

Most of the funding amount (70%) was raised in 2020 and 2021. It is worth highlighting that majority of the amount in this domain has been raised through venture capital funding. It is important to note that more than 190 investors have actively financed projects / initiatives in this domain.

Over 365 clinical trials evaluating allogeneic cell therapies have been registered worldwide, since 2019 

The investigation of allogeneic cell therapies has gained significant traction from various industry as well as non-industry players. Around 90% of the clinical trials in this domain are currently active. Further, more than 50% of the trials are in Phase I, enrolling around 7,450 patients. 

North America is anticipated to capture over 85% of the market share, by 2035

Currently, majority share (~90%) of the overall allogeneic cell therapy market is captured by stem cell therapies; this trend is unlikely to change in the foreseen future as well. Further, by 2035, more than 45% of the market share is likely to be captured by allogeneic cell therapies derived from bone marrow / bone matrix. In terms of therapeutic area, allogeneic cell therapies being developed for post-transplant infections are expected to dominate the market, by 2035. 

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • What is allogeneic cell therapy?
  • What is allogeneic vs autologous cell therapy? 
  • What are the advantages of allogeneic cell therapy? 
  • Which are the most common sources from which allogeneic cells can be derived?
  • Who are the key players engaged in developing allogeneic cell therapies?
  • Which agreement models are commonly adopted by stakeholders in this industry?
  • What are the key market trends and driving factors that are likely to impact this market?
  • What is the current / likely future market size of allogeneic cell therapy market?
  • Which type of cell therapy is likely to have the largest market share in the allogeneic cell therapy market?
  • Which region captures the largest share of the allogeneic cell therapy market?

The financial opportunity within the allogeneic cell therapy market has been analyzed across the following segments:

  • Type of Cell Therapy
    • Stem Cell 
    • Virus-Specific T-Cell
    • Regulatory T-Cell
  • Source of Cell
    • Bone Marrow / Matrix
    • Adipose Tissue
    • Peripheral Blood
    • Umbilical Cord
    • Placenta
    • Others
  • Target Indication
    • Infectious Diseases
    • Chronic Heart Failure
    • Crohn’s Disease
    • Ischemic Stroke
    • Hematological Cancer
    • Bone Diseases
    • Critical Limb Ischemia
    • Graft versus Host Disease
    • Duchenne Muscular Dystrophy
    • Epidermolysis Bullosa
    • Diabetic Foot Ulcer
    • Others
  • Therapeutic Area
    • Post-Transplant Infections
    • Cardiovascular Disorders
    • Autoimmune / Inflammatory Disorders
    • Cerebrovascular Disorders
    • Oncological Disorders
    • Musculoskeletal Disorders
    • Neurological Disorders
    • Genetic Disorders
    • Others
  • Key Geographical Regions 
    • North America
    • Europe
    • Asia-Pacific and Rest of the World 

The report also features inputs from eminent industry stakeholders, according to whom, the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results is likely to drive the growth of the overall allogeneic cell therapy market, in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:

For additional details, please visit or email 

You may also be interested in the following titles

  1. Bispecific Antibodies (5th Edition) Market: Industry Trends and Global Forecasts, 2023-2035
  2. Global Antibiotics Market: Industry Trends and Global Forecasts, 2023-2035
  3. Gene Switch Market: Industry Trends and Global Forecasts, 2023-2035
  4. Cell Therapy Media, Cell Therapy Kits, and Cell Therapy Surface (2nd Edition) Market: Industry Trends and Global Forecasts, 2023-2035
  5. Global TIL Therapies Market (2nd Edition), Market: Industry Trends and Global Forecasts, 2023-2035
  6. Monkeypox Treatment Market: Industry Trends and Global Forecasts, 2023-2035

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry